150 related articles for article (PubMed ID: 9668586)
1. Effect of oral iron chelator L1 on iron absorption in man.
Dresow B; Fischer R; Nielsen P; Gabbe EE; Piga A
Ann N Y Acad Sci; 1998 Jun; 850():466-8. PubMed ID: 9668586
[No Abstract] [Full Text] [Related]
2. Pharmacokinetic disposition of the oral iron chelator deferiprone in the domestic pigeon (Columba livia).
Whiteside DP; Barker IK; Conlon PD; Tesoro A; Thiessen JJ; Mehren KG; Jacobs RM; Spino M
J Avian Med Surg; 2007 Jun; 21(2):121-9. PubMed ID: 18065133
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic disposition of the oral iron chelator deferiprone in the white leghorn chicken.
Whiteside DP; Barker IK; Conlon PD; Tesoro A; Thiessen JJ; Mehren KG; Jacobs RM; Spino M
J Avian Med Surg; 2007 Jun; 21(2):110-20. PubMed ID: 18065132
[TBL] [Abstract][Full Text] [Related]
4. Acute iron intoxication: the efficacy of deferiprone and sodium biocarbonate in the prevention of iron absorption from the digestive tract.
Barr J; Berkovitch M; Tavori I; Kariv N; Schejter A; Eshel G
Vet Hum Toxicol; 1999 Oct; 41(5):308-11. PubMed ID: 10509434
[TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels.
Fassos FF; Klein J; Fernandes D; Matsui D; Olivieri NF; Koren G
Int J Clin Pharmacol Ther; 1996 Jul; 34(7):288-92. PubMed ID: 8832304
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment with deferiprone in a L1 veteran.
Meo A; Ruggeri A; La Rosa MA; Zanghì L; Kordes U; Fischer R
Eur J Haematol; 2005 Jun; 74(6):523-5. PubMed ID: 15876257
[TBL] [Abstract][Full Text] [Related]
7. Liver iron depletion and toxicity of the iron chelator deferiprone (L1, CP20) in the guinea pig.
Wong A; Alder V; Robertson D; Papadimitriou J; Maserei J; Berdoukas V; Kontoghiorghes G; Taylor E; Baker E
Biometals; 1997 Oct; 10(4):247-56. PubMed ID: 9353871
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the effect of the oral iron chelator deferiprone on asymptomatic Plasmodium falciparum parasitemia in humans.
Thuma PE; Olivieri NF; Mabeza GF; Biemba G; Parry D; Zulu S; Fassos FF; McClelland RA; Koren G; Brittenham GM; Gordeuk VR
Am J Trop Med Hyg; 1998 Mar; 58(3):358-64. PubMed ID: 9546419
[TBL] [Abstract][Full Text] [Related]
9. Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia.
Matsui D; Klein J; Hermann C; Grunau V; McClelland R; Chung D; St-Louis P; Olivieri N; Koren G
Clin Pharmacol Ther; 1991 Sep; 50(3):294-8. PubMed ID: 1914364
[TBL] [Abstract][Full Text] [Related]
10. Clinical trials with oral iron chelator L1.
Kontoghiorghes GJ; Hoffbrand AV
Lancet; 1989 Dec 23-30; 2(8678-8679):1516-7. PubMed ID: 2574781
[No Abstract] [Full Text] [Related]
11. The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1).
Berdoukas V; Bohane T; Eagle C; Lindeman R; DeSilva K; Tobias V; Painter D; Fraser I
Transfus Sci; 2000 Dec; 23(3):239-40. PubMed ID: 11099900
[No Abstract] [Full Text] [Related]
12. Characterisation of a novel oral iron chelator: 1-(N-Acetyl-6-Aminohexyl)-3-Hydroxy-2-Methylpyridin-4-one.
Pangjit K; Banjerdpongchai R; Phisalaphong C; Fucharoen S; Xie YY; Lu ZD; Hider RC; Srichairatanakool S
J Pharm Pharmacol; 2015 May; 67(5):703-13. PubMed ID: 25627251
[TBL] [Abstract][Full Text] [Related]
13. Methodological issues in studying the effect of the new oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) on absorption of iron.
Bentur Y; Klein J; Levy M; Olivieri N; McGuigan M; Koren G
Vet Hum Toxicol; 1990 Apr; 32(2):159-61. PubMed ID: 2327067
[TBL] [Abstract][Full Text] [Related]
14. Intestinal absorption and enterohepatic cycling of biliary iron originating from plasma non-transferrin-bound iron in rats.
Brissot P; Bolder U; Schteingart CD; Arnaud J; Hofmann AF
Hepatology; 1997 Jun; 25(6):1457-61. PubMed ID: 9185768
[TBL] [Abstract][Full Text] [Related]
15. Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats.
Kontoghiorghes GJ; Sheppard L; Hoffbrand AV; Charalambous J; Tikerpae J; Pippard MJ
J Clin Pathol; 1987 Apr; 40(4):404-8. PubMed ID: 3584483
[TBL] [Abstract][Full Text] [Related]
16. Iron mobilisation from transferrin by deferiprone (L1).
Kontoghiorghes GJ; Kolnagou A; Eracleous E; Evans RW
Br J Haematol; 2005 Apr; 129(1):157. PubMed ID: 15801969
[No Abstract] [Full Text] [Related]
17. Pharmaco/ferrokinetic-related pro-oxidant activity of deferiprone in beta-thalassemia.
Jirasomprasert T; Morales NP; Limenta LM; Sirijaroonwong S; Yamanont P; Wilairat P; Fucharoen S; Chantharaksri U
Free Radic Res; 2009 May; 43(5):485-91. PubMed ID: 19353420
[TBL] [Abstract][Full Text] [Related]
18. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
Barman Balfour JA; Foster RH
Drugs; 1999 Sep; 58(3):553-78. PubMed ID: 10493280
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of deferiprone in patients with β-thalassaemia: impact of splenectomy and iron status.
Limenta LM; Jirasomprasert T; Jittangprasert P; Wilairat P; Yamanont P; Chantharaksri U; Fucharoen S; Morales NP
Clin Pharmacokinet; 2011 Jan; 50(1):41-50. PubMed ID: 21028920
[TBL] [Abstract][Full Text] [Related]
20. Effect of the oral iron chelator deferiprone in diabetic nephropathy rats.
Zou C; Liu X; Liu R; Wang M; Sui M; Mu S; Li L; Ji L; Xie R
J Diabetes; 2017 Apr; 9(4):332-340. PubMed ID: 27121697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
